“`html
Seoul,South Korea – A groundbreaking study from Yonsei Cancer Hospital has identified the MET gene as a pivotal target for treatment across a spectrum of solid cancers,including lung and stomach cancer,potentially expanding therapeutic options beyond its current application in non-small cell lung cancer (NSCLC).
The research, spearheaded by Professor Cho Byung-chul, Professor Lee Ki-jung, and Major Shim Ju-sung from Yonsei Cancer Hospital’s Oncology Department, suggests that targeting the MET gene, which is often overexpressed in various carcinomas, could become a standard strategy for a wider range of patients. These findings were recently published in the prestigious journal Nature Reviews Clinical Oncology, known for its high impact factor of 82.2.
The MET gene plays a critical role in the proliferation and metastasis of cancer cells.Clinically, targeting MET gene overexpression has demonstrated meaningful efficacy in patients with NSCLC. This new research indicates that this targeted approach can be extended to other solid tumors, such as colon and stomach cancers, where MET gene abnormalities are also prevalent.
The study highlights the importance of early detection of MET gene overexpression and optimizing treatment timing to maximize anti-cancer effects.Moreover, the research team noted that MET gene-targeted therapies are being actively investigated in combination with immunotherapies and antibody-drug conjugates
